NASDAQ:CERC Cerecor (CERC) Stock Price, News & Analysis → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free CERC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.30▼$11.6150-Day Range$2.06▼$3.2452-Week Range$1.98▼$4.50Volume28,142 shsAverage Volume1.27 million shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsInsider TradesTrendsStock AnalysisCompetitorsInsider TradesTrends Get Cerecor alerts: Email Address Ad Behind the MarketsAre you prepared for a Chinese "invasion?"Recently declassified documents show that while the U.S has been distracted in the Middle East... China had been studying our every move... And preparing themselves for not only an armed conflict with the United StatesHere are 4 steps you can take RIGHT NOW >>> About Cerecor Stock (NASDAQ:CERC)Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Read More Ad Behind the MarketsAre you prepared for a Chinese "invasion?"Recently declassified documents show that while the U.S has been distracted in the Middle East... China had been studying our every move... And preparing themselves for not only an armed conflict with the United StatesHere are 4 steps you can take RIGHT NOW >>> CERC Stock News HeadlinesDecember 19, 2023 | benzinga.comAytu BioPharma Stock (NASDAQ:AYTU) Insider TradesAugust 24, 2023 | uk.finance.yahoo.commTOR Inhibitors Global Market Report 2023June 18, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 11, 2023 | finance.yahoo.comDelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline LandscapeSeptember 28, 2022 | finance.yahoo.comEdited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT - Yahoo FinanceSeptember 28, 2022 | seekingalpha.comAytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript - Seeking AlphaAugust 31, 2022 | marketwatch.comDiGeorge Syndrome Drug Market In-Depth Analysis Research Report 2029August 24, 2022 | streetinsider.comValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - StreetInsider.comJune 18, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.August 24, 2022 | businesswire.comValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - Business WireAugust 11, 2022 | globenewswire.comCelldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswireAugust 9, 2022 | streetinsider.comCelldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - StreetInsider.comAugust 8, 2022 | marketscreener.comCelldex Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K - Marketscreener.comJuly 24, 2022 | seekingalpha.comAvalo Therapeutics, Inc. (AVTX) Stock Price Today, Quote & News - Seeking AlphaJuly 15, 2022 | bizjournals.comPhiladelphia biotech news: Updates from CHOP, Helius Medical, GSK and more - Philadelphia Business Journal - The Business JournalsMay 3, 2022 | prnewswire.comThe Axial Spondyloarthritis Market is Predicted to Grow with a CAGR of 4.7% by 2032, Analyzes DelveInsight - PR NewswireMay 1, 2022 | marketwatch.comDiGeorge Syndrome Drug Market Size, Share, Industry Growth & Forecast By 2029April 8, 2022 | marketscreener.comAACR Poster Presentation: CFT7455 Phase 1/2 Cohort A - Marketscreener.comMarch 28, 2022 | benzinga.comDiGeorge Syndrome Drug Market High Demand, Size, Share, Processing Industry, And Forecast By 2029 - Benzi - BenzingaNovember 10, 2021 | businesswire.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Business WireNovember 10, 2021 | nasdaq.comModel N (MODN) Q4 Earnings & Revenues Top Estimates, Up Y/Y - NasdaqNovember 9, 2021 | finance.yahoo.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Yahoo FinanceNovember 9, 2021 | finance.yahoo.comAvalo Reports Third Quarter 2021 Financial Results and Provides Business Updates - Yahoo FinanceNovember 9, 2021 | stockhouse.comModel N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - StockhouseOctober 7, 2021 | finance.yahoo.comHorizon Technology Finance Provides Third Quarter 2021 Portfolio Update - Yahoo FinanceAugust 27, 2021 | bizjournals.comInovio's experimental Covid-19 vaccine takes another step, plus other life sciences news - Philadelphia Business Journal - Philadelphia Business JournalAugust 27, 2021 | marketscreener.comCERECOR : Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc (Form 8-K) - Marketscreener.comSee More Headlines Receive CERC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2021Today6/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CERC CUSIPN/A CIK1534120 Webwww.cerecor.com Phone(410) 522-8707FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,500,000.00 Net Margins-1,194.82% Pretax MarginN/A Return on Equity-261.82% Return on Assets-133.96% Debt Debt-to-Equity Ratio0.79 Current Ratio2.19 Quick Ratio2.18 Sales & Book Value Annual Sales$6.70 million Price / Sales156.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book49.68Miscellaneous Outstanding Shares96,009,000Free FloatN/AMarket Cap$1.05 billion OptionableNot Optionable Beta1.44 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMichael F. ColaChairman & Chief Executive OfficerSchond L. GreenwayChief Financial Officer & TreasurerH. Jeffrey WilkinsChief Medical OfficerGarry Arthur NeilChief Scientific OfficerYounok Dumortier ShinChief Technology OfficerKey CompetitorsSierra OncologyNASDAQ:SRRALexicon PharmaceuticalsNASDAQ:LXRXStrongbridge BiopharmaNASDAQ:SBBPAssembly BiosciencesNASDAQ:ASMBSol-Gel TechnologiesNASDAQ:SLGLView All Competitors CERC Stock Analysis - Frequently Asked Questions How were Cerecor's earnings last quarter? Cerecor Inc. (NASDAQ:CERC) posted its earnings results on Sunday, August, 1st. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. The company had revenue of $3.36 million for the quarter. Cerecor had a negative trailing twelve-month return on equity of 261.82% and a negative net margin of 1,194.82%. What other stocks do shareholders of Cerecor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Novan (NOVN), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). This page (NASDAQ:CERC) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredAvoid These AI Stocks Like the Plague...Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh co...Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.